184 related articles for article (PubMed ID: 32920508)
41. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.
Vedvyas Y; McCloskey JE; Yang Y; Min IM; Fahey TJ; Zarnegar R; Hsu YS; Hsu JM; Van Besien K; Gaudet I; Law P; Kim NJ; Hofe EV; Jin MM
Sci Rep; 2019 Jul; 9(1):10634. PubMed ID: 31337787
[TBL] [Abstract][Full Text] [Related]
42. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
43. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
[TBL] [Abstract][Full Text] [Related]
44. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A; Valeri A; Córdoba L; García-Ortiz A; Ortiz A; Sánchez-Vega L; Graña-Castro O; Fernández L; Carreño-Tarragona G; Pérez M; Megías D; Paciello ML; Sánchez-Pina J; Pérez-Martínez A; Lee DA; Powell DJ; Río P; Martínez-López J
Blood Cancer J; 2021 Aug; 11(8):146. PubMed ID: 34392311
[TBL] [Abstract][Full Text] [Related]
45. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells.
He Y; Li XM; Yin CH; Wu YM
J Reprod Immunol; 2020 Jun; 139():103115. PubMed ID: 32199196
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
[TBL] [Abstract][Full Text] [Related]
47. The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M; Steinle A
Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
[TBL] [Abstract][Full Text] [Related]
48. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
49. shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer.
Zhang H; Yao J; Ajmal I; Farooq MA; Jiang W
Front Immunol; 2024; 15():1369406. PubMed ID: 38835760
[TBL] [Abstract][Full Text] [Related]
50. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
51. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.
Deng C; Zhao J; Zhou S; Dong J; Cao J; Gao J; Bai Y; Deng H
Mol Ther; 2020 Jan; 28(1):75-88. PubMed ID: 31672285
[TBL] [Abstract][Full Text] [Related]
52. Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.
Marei HE; Althani A; Caceci T; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Roselli M; Caratelli S; Cenciarelli C; Sconocchia G
Biochem Pharmacol; 2019 Aug; 166():335-346. PubMed ID: 31176617
[TBL] [Abstract][Full Text] [Related]
53. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G
Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441
[TBL] [Abstract][Full Text] [Related]
54. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
55. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
56. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
57. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208
[TBL] [Abstract][Full Text] [Related]
58. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
59. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
60. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Michaux A; Mauën S; Breman E; Dheur MS; Twyffels L; Saerens L; Jacques-Hespel C; Gauthy E; Agaugué S; Gilham DE; Sotiropoulou PA
J Immunother; 2022 Apr; 45(3):150-161. PubMed ID: 35191428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
